Based on the successful clinical experience with the anti-CD20 antibody, rituximab, for the treatment of B-cell non-Hodgkins lymphoma, there is a rapidly growing literature on the treatment of patients with autoimmune diseases with this therapeutic agent. However, the pathogenetic mechanisms responsible for these diseases may differ greatly from those in B cell malignancies. Herein, I provide a...

We describe eight cases of primary cerebral lymphoma seen in Manitoba from 1980 to 1985. The clinical presentation is similar to other primary brain tumors. The diagnosis should be considered when single or multiple, often deep lesions, show dense enhancement on computerized tomographic (CT) scan, but are avascular at angiography. These tumors are histologically indistinguishable from non-Hodgk...

Midline destructive lesions of the face have multiple possible etiologies. The majority of these cases are found to be due to an extranodal lymphoma of natural killer/T-cell-type non-Hodgkins lymphoma (NKTL). Unfortunately, diagnosis is often delayed. With variable presenting complaints, including nonspecific issues like chronic rhinosinusitis or nasal congestion, initial treatments are aimed a...

Rituximab (Rituxan) is a genetically engineered chimeric murine/human monoclonal antibody and the first monoclonal antibody to become available to physicians for the treatment of malignant disease. It has recently been licensed for use in the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive B-cell Non-Hodgkins Lymphoma (NHL). Its mechanism of action is by...

myeloid sarcoma (ms) is a tumor mass consisting of myeloblast with or without maturation occurring at an anatomical site other than the bone marrow. incidence of ms ranges from 1-9% and is most commonly misdiagnosed as non hodgkins lymphoma or poorly differentiated carcinoma. ms can occur in various sites but nasal cavity involvement is rare. here we report acaseof ms presenting as nasal polyp ...